Efficacy and safety of different conbercept injection regimens in the treatment of choroidal neovascularization in pathological myopia: a retrospective study.
Best-corrected visual acuity
Central retinal thickness
Choroidal neovascularization
Conbercept
Pathological myopia
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
19
11
2021
accepted:
09
07
2023
medline:
26
9
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
To investigate the clinical efficacy of conbercept 1 + pro re nata (PRN) (i.e., reinjection as needed after one injection) and 3 + PRN (reinjection as needed after 3 months of injection) regimens in choroidal neovascularization secondary to pathological myopia (PM-CNV). From 06/2019 to 06/2020, 65 patients (65 eyes) confirmed with PM-CNV were included in this retrospective study. Intravitreal injection of 0.5 mg conbercept was conducted either with the 1 + PRN or 3 + PRN strategy. Patients were followed up for 12 months. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), CNV lesion leakage area, the number of injections, and postoperative adverse reactions were observed. The mean age of the patients was 42.10 ± 4.69 years, and the average diopter was - 11.26 ± 2.97D. The BCVA at month 3 in the 3 + PRN (n = 30) group was lower than in the 1 + PRN (n = 35) group (P < 0.001). The CRT at month 3 in the 3 + PRN group was lower than in the 1 + PRN group (P < 0.001). After 12 months, there were no differences in the BCVA and CRT between the two groups (P > 0.05). The number of injections was less in 1 + PRN than in 3 + PRN (2.14 ± 1.06 vs. 3.37 ± 0.76, P < 0.001) at 12 months. No serious treatment-related ocular complications or serious systemic adverse events were found. The 1 + PRN and 3 + PRN strategies of intravitreal injection of conbercept are effective in treating PM-CNV. The 1 + PRN regimen required fewer injections, and it might be more suitable for the treatment of PM-CNV.
Identifiants
pubmed: 37523104
doi: 10.1007/s10792-023-02825-9
pii: 10.1007/s10792-023-02825-9
doi:
Substances chimiques
KH902 fusion protein
1P05PW62F3
Angiogenesis Inhibitors
0
Recombinant Fusion Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4079-4086Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Ohno-Matsui K, Kawasaki R, Jonas JB, Cheung CM, Saw SM, Verhoeven VJ, Klaver CC, Moriyama M, Shinohara K, Kawasaki Y, Yamazaki M, Meuer S, Ishibashi T, Yasuda M, Yamashita H, Sugano A, Wang JJ, Mitchell P, Wong TY (2015) International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol 159(5):877–83.e7. https://doi.org/10.1016/j.ajo.2015.01.022
doi: 10.1016/j.ajo.2015.01.022
pubmed: 25634530
Williams KM, Bertelsen G, Cumberland P, Wolfram C, Verhoeven VJ, Anastasopoulos E, Buitendijk GH, Cougnard-Grégoire A, Creuzot-Garcher C, Erke MG, Hogg R, Höhn R, Hysi P, Khawaja AP, Korobelnik JF, Ried J, Vingerling JR, Bron A, Dartigues JF, Fletcher A, Hofman A, Kuijpers RW, Luben RN, Oxele K, Topouzis F, von Hanno T, Mirshahi A, Foster PJ, van Duijn CM, Pfeiffer N, Delcourt C, Klaver CC, Rahi J, Hammond CJ (2015) Increasing prevalence of myopia in europe and the impact of education. Ophthalmology 122(7):1489–1497. https://doi.org/10.1016/j.ophtha.2015.03.018
doi: 10.1016/j.ophtha.2015.03.018
pubmed: 25983215
Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110(7):1297–1305. https://doi.org/10.1016/s0161-6420(03)00461-5
doi: 10.1016/s0161-6420(03)00461-5
pubmed: 12867382
Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, Tokoro T, Mochizuki M (2003) Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 87(5):570–573. https://doi.org/10.1136/bjo.87.5.570
doi: 10.1136/bjo.87.5.570
pubmed: 12714395
pmcid: 1771643
Zhu Y, Zhang T, Xu G, Peng L (2016) Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 12(12):Cd011160. https://doi.org/10.1002/14651858.CD011160.pub2
Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141(3):456–462. https://doi.org/10.1016/j.ajo.2005.10.012
doi: 10.1016/j.ajo.2005.10.012
pubmed: 16490490
Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM (2018) Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92–106. https://doi.org/10.1016/j.preteyeres.2017.10.005
Kasahara K, Moriyama M, Morohoshi K, Yoshida T, Simada N, Nagaoka N, Yokoi T, Shinohara K, Kaneko Y, Suga M, Ohno-Matsui K (2017) Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia. Retina 37(6):1055–1064. https://doi.org/10.1097/iae.0000000000001313
doi: 10.1097/iae.0000000000001313
pubmed: 27755380
Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Yang Y, Andrews C, Brittain C, Osborne A (2013) Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond) 27(6):709–715. https://doi.org/10.1038/eye.2013.8
doi: 10.1038/eye.2013.8
pubmed: 23449508
Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, Mitchell P, Ohno-Matsui K, Chen SJ, Wolf S, Wong TY (2017) Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 124(11):1690–1711. https://doi.org/10.1016/j.ophtha.2017.04.028
doi: 10.1016/j.ophtha.2017.04.028
pubmed: 28655539
Wang E, Chen Y (2013) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 33(7):1375–1392. https://doi.org/10.1097/IAE.0b013e31827d260a
doi: 10.1097/IAE.0b013e31827d260a
pubmed: 23514793
Calvo-González C, Reche-Frutos J, Fernández-Vigo JI, Sáenz-Francés F, Fernández-Pérez C, García-Feijóo J (2017) Long-term outcomes of two different initial dosing regimens of intravitreal Ranibizumab used to treat myopic choroidal neovascularization. Ophthalmologica 238(4):196–204. https://doi.org/10.1159/000478030
doi: 10.1159/000478030
pubmed: 28881344
Kung YH, Wu TT, Huang YH (2014) One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol 92(8):e615–e620. https://doi.org/10.1111/aos.12457
doi: 10.1111/aos.12457
pubmed: 24924911
Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi T (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122(6):1220–1227. https://doi.org/10.1016/j.ophtha.2015.01.025
doi: 10.1016/j.ophtha.2015.01.025
pubmed: 25745875
Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, Li H (2009) The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 26(1):204–210. https://doi.org/10.1007/s11095-008-9718-9
doi: 10.1007/s11095-008-9718-9
pubmed: 18854954
Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, Luo D, Ke X (2014) Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121(9):1740–1747. https://doi.org/10.1016/j.ophtha.2014.03.026
doi: 10.1016/j.ophtha.2014.03.026
pubmed: 24793528
Liu K, Wang H, He W, Ye J, Song Y, Wang Y, Liu X, Wu Z, Chen S, Fan K, Liu Y, Zhang F, Li Z, Liu L, Zhang J, Zhang X, Ye J, Liang X, Li X, Ke X, Wu Q, Li J, Tao S, Wang X, Rosenfeld P, Heier JS, Kaiser P, Xu X (2021) Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2020-318690
doi: 10.1136/bjophthalmol-2020-318690
pubmed: 34952836
Yan M, Huang Z, Lian HY, Song YP, Chen X (2019) Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol 97(5):e813–e814. https://doi.org/10.1111/aos.13632
doi: 10.1111/aos.13632
pubmed: 30187680
Nie X, Wang Y, Yi H, Qiao Y (2021) Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China: intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. BMC Ophthalmol 21(1):116. https://doi.org/10.1186/s12886-021-01877-8
doi: 10.1186/s12886-021-01877-8
pubmed: 33663431
pmcid: 7934258
Keane PA, Liakopoulos S, Chang KT, Heussen FM, Ongchin SC, Walsh AC, Sadda SR (2008) Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol 92(8):1081–1085. https://doi.org/10.1136/bjo.2008.138891
doi: 10.1136/bjo.2008.138891
pubmed: 18586903
Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ (2021) Risk of systemic adverse events after intravitreal bevacizumab, Ranibizumab, and Aflibercept in routine clinical practice. Ophthalmology 128(3):417–424. https://doi.org/10.1016/j.ophtha.2020.07.062
doi: 10.1016/j.ophtha.2020.07.062
pubmed: 32781110
Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, Kim JW (2015) Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 159(2):285–92.e1. https://doi.org/10.1016/j.ajo.2014.10.035
doi: 10.1016/j.ajo.2014.10.035
pubmed: 25447115
Schütze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U (2015) Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol 159(6):1100-1114.e1. https://doi.org/10.1016/j.ajo.2015.02.020
doi: 10.1016/j.ajo.2015.02.020
pubmed: 25769245
pmcid: 4430174
Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121(3):682–92.e2. https://doi.org/10.1016/j.ophtha.2013.10.023
doi: 10.1016/j.ophtha.2013.10.023
pubmed: 24326106
Lu X, Sun X (2015) Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther 9:2311–2320. https://doi.org/10.2147/dddt.S67536
doi: 10.2147/dddt.S67536
pubmed: 25960634
pmcid: 4410828
Yao TT, Jin XL, Yang Y, Wang YX, Zhou YL, He FL, Wang ZY (2020) Intraocular pharmacokinetics and safety of subretinal injection compared with intravitreal application of conbercept in vitrectomized rabbit eyes. J Ophthalmol 2020:2674780. https://doi.org/10.1155/2020/2674780
doi: 10.1155/2020/2674780
pubmed: 32280518
pmcid: 7125476